Skip to content

Clinical research based on Liuweibuqi capsule used the Gubenbuqi method of Xinan medicine intervented the stabilized phrase of chronic obstructive pulmonary disease and lung and kidney deficiency syndrome

Clinical research based on Liuweibuqi capsule used the Gubenbuqi method of Xinan medicine intervented the stabilized phrase of chronic obstructive pulmonary disease and lung and kidney deficiency syndrome

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15007208
Enrollment
Unknown
Registered
2015-10-12
Start date
2015-12-22
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

2:Liuweibuqi capsule vs medication

Sponsors

The first affiliated Hospital Of Anhui University Of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Comply with the diagnostic criteria of COPD patients; 2. Conform to the lung and kidney deficiency syndrome; 3. Degree of condition of mild, moderate and severe patients with plateau; 4. At the age of 40 age 75 years old or less or less; 5. Rounding out the top one month does not attend other interventions in clinical research; 6. Voluntary treatment, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with acute aggravating period of COPD; 2. Belongs to very severe COPD patients with plateau condition; 3. Do not meet above TCM syndrome types; 4. Pregnancy and lactation women; 5. Delirious, dementia, all kinds of mental illness; 6. Cardiac function grade ? and hemodynamic instability; 7. Combination of bronchiectasis, bronchial asthma, active tuberculosis, occlusive bronchiolitis, diffuse bronchiolitis, pleural effusion, pulmonary embolism, pneumothorax patients; 8. The neuromuscular diseases affect respiratory movement function; 9. Merger of tumor; 10. Severe liver and kidney diseases (severe liver disease refers to cirrhosis, portal hypertension and varices bleeding, severe kidney disease including dialysis, kidney transplantation); 11. A variety of reasons in long-term; 12. Rounding out the top 1 months of oral corticosteroids; 13. Congenital or acquired immune deficiency; 14. Taking part in clinical subjects of other drugs, known for treatment of drug allergy.

Design outcomes

Primary

MeasureTime frame
Number of COPD exacerbations;pulmonary function;

Secondary

MeasureTime frame
clinical symptoms;Evaluation of TCM symptomatology;mrc dyspnea scale;six-minute walk distance;quality of life;Drug combination situation;

Countries

China

Contacts

Public ContactZegeng Li
li6609@126.com+86 13805516609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026